Heart rate slowing by If inhibition: Therapeutic utility from clinical trials

European Heart Journal, Supplement

Volumn 7, Issue H, 2005, Pages

  Borer, Jeffrey S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angina pectoris; Cardiovascular pharmacology; Coronary artery disease

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; IVABRADINE; MONOAMINE OXIDASE INHIBITOR; NITRIC ACID DERIVATIVE; ZATEBRADINE;

ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART DEPOLARIZATION; HEART RATE; HUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RETINA INJURY; SINUS NODE; VISUAL DISORDER; WITHDRAWAL SYNDROME;

EID: 24744461912     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui050     Document Type: Article

References (47)

1. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18:394-413.
2. Gibbons RJ, Chatterjee K, Daley J et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. Circulation 1999;99:2829-2848.
3. Williams SV, Fihn SD, Gibbons RJ. Guidelines for the management of patients with chronic stable angina: diagnosis and risk stratification. Ann Int. Med 2001;135:530-547.
4. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003;284:H676-H682.
5. Colin P, Ghaleh B, Monnet X et al. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004;308:236-240.
6. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart-rate are associated with coronary plaque disruption. Circulation 2001;104:1477-1482.
7. Habib G. Is heart rate a risk factor in the general population? Dialogues Cardiovasc Med 2001;6:25-31.
8. Goldberg R, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women: The Framingham Study. Arch Intern Med 1996;156:505-509.
9. Gillum R. The epidemiology of resting heart rate in a national sample of men and women: association with hypertension, coronary artery disease, blood pressure, and other cardiovascular risk factors. Am Heart J 1988;116:163-174.
10. f Channel Inhibition in Cardiology. London: Science Press Ltd; 2004. p25-36.
11. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 3rd ed. Philadelphia: W.B. Saunders; 1988. p1330.
12. Frishman WH, Sica DA. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapies. 2nd ed. New York: McGraw-Hill; 2003. p105-130.
13. Epstein SE, Beiser GD, Goldstein RE et al. Treatment of angina pectoris by electrical stimulation of the carotid sinus nerves. N Eng J Med 1969;280:971-978.
14. Dargie HJ, Ford I, Fox K et al. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina The TIBET study group. Eur Heart J 1997;17:104-112.
15. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature 1979;280:235-236.
16. f) induced by acetylcholine in rabbit sino-atrial node myocytes. J Physiol (Lond) 1988;405:477-491.
17. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991;434:23-40.
18. Borer JS. Development of cardiovascular drugs: the U.S. regulatory milieu from the perspective of a participating non-regulator. J Am Coll Cardiol 2004;44:2285-2292.
19. f in rabbit sinoatrial node cells by zatebradine (UL-FS 49). On the mode of action of sinus node inhibitors. Circulation 1993;88:2389-2401.
20. Frishman WH, Pepine CJ, Weiss RJ et al. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomised, double-blind, placebo-controlled, parallel-group study. J Am Coll Cardiol 1995;26:305-312.
21. Frishman WH, Retter A, Misailidis J et al. Innovative pharmacologic approaches to treatment of myocardial ischemia. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapies. 2nd ed. New York: McGraw-Hill; 2003. p655-690.
22. Thollon C, Cambarrat C, Vian J et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea pig-cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994;112:37-42.
23. Simon L, Ghaleh B, Puybasset L et al. Coronary and haemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharm Exp Ther 1995;275:659-666.
24. Colin P, Ghaleh B, Hittinger L et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 2002;282:H672-H679.
25. Moore N, Joannides R, Iacob M et al. Effects of a pure bradycardic agent, S 16257, at rest and during exercise in healthy volunteers: comparison with propranolol. Br J Clin Pharm 1998;45:188-189.
26. Manz M, Reuter M, Lauck G et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003;100:149-155.
27. Monnet X, Ghaleb B, Colin P et al. Effect of heart rate reduction with ivabradine on exercise induced myocardial ischaemia and stunning. J Pharm Exp Ther 2001;299:1133-1139.
28. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004;64:1757-1765.
29. Thollon C, Bidouard JP, Cambarrat C et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 1997;339:43-51.
30. f inhibitors as specific heart rate reducing agents. Nature (Clin Pract Cardiovasc) 2004;1:103-109.
31. Lipicky RJ. Natural history endpoints and angina trials. In: Borer JS, Somberg JC, eds. Cardiovascular Drug Development: Protocol Design and Methodology. New York: Marcel Dekker; 1999. p185-187.
32. f inhibitor, in stable angina: a randomized, double-blinded, multi-centered, placebo-controlled trial. Circulation 2003;107:817-823.
33. f current inhibitor ivabradine compared to atenolol as monotherapies in patients with chronic stable angina. A 4-month randomised, double-blinded, multicenter, controlled non-inferiority trial. Eur Heart J 2003;24(Suppl.):20.
34. Ruzyllo W, Ford IF, Tendera MT, et al. on behalf of the study investigators. Anti-anginal and anti-ischaemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial. Eur Heart J 2004;25(Suppl.):138.
35. f current inhibitor ivabradine in patients with chronic stable angina. A one year randomised, double-blind, multicentre trial. Eur Heart J 2004;25(Suppl.):138.
36. Pepine CJ, Abrams J, Marks RG et al. Characteristics of a contemporary population with angina pectoris: TIDES Investigators. Am J Cardiol 1994;74:226-231.
37. Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs: an update. Drug Safety 1993;9:272-279.
38. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther 1991;4(Suppl. 6):1229-1232.
39. Ramahi TM. Beta blocker therapy for chronic heart failure. Am Fam Physician 2000;62:2267-2274.
40. Reneland R, Alvarez E, Andersson PE et al. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000;14:175-180.
41. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988;116:1729-1734.
42. Abrams J, Frishman WH. The organic nitrates and nitroprusside. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapies. New York: McGraw-Hill; 2003. p203-214.
43. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol 1988;61:1219-1222.
44. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy in continuous twenty-four hour application of transdermal nitroglycerin. Am J Cardiol 1991;68:1263-1270.
45. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997;30:1104-1106.
46. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999;1(Suppl. H):H64-H69.
47. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial intervention trials. Am J Cardiol 1986;57:43F-49F.